Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 17;12(1):10266.
doi: 10.1038/s41598-022-14387-4.

Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion

Eva Perelló-Camacho  1 , Francisco J Pomares-Gómez  2 , Luis López-Penabad  2 , Rosa María Mirete-López  2 , María Rosa Pinedo-Esteban  2 , José Ramón Domínguez-Escribano  2
Affiliations

Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion

Eva Perelló-Camacho et al. Sci Rep. .

Abstract

The aim of this work is to examine our experience in the use of urea in patients with SIADH. Observational retrospective analysis of 48 patients with SIADH that have been treated with urea in a third-level hospital. Pre-post analysis of serum sodium levels. The 48 patients with SIADH had a median age of 78.5 (range 26-97 years). The serum sodium nadir was 119.8 ± 5.0 mmoL/L and at the beginning of treatment 125.6 ± 4.1 mmoL/L. The patients continued the treatment for a mean time of 2.95 ± 6.29 months, being the treatment still active in 4 patients. In all patients there was an improvement in serum sodium, being the final serum sodium at the end of treatment 134.4 ± 4.9 mmoL/L (p < 0.01). This improvement was observed from the first week. Adverse events were only detected in 2 patients with mild digestive symptomatology and 2 patients refused the treatment due to the low palatability of the urea. There was an economic cost reduction of 87.9% in comparison with treatment with tolvaptan. Urea has shown to be a safe and cost-effective option for the treatment of hyponatremia caused by SIADH.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Evolution of sodium levels with urea treatment.
See this image and copyright information in PMC

References

    1. Peri A. Management of hyponatremia: causes, clinical aspects, differential diagnosis and treatment. Expert Rev. Endocrinol. Metab. 2019;14(1):13–21. doi: 10.1080/17446651.2019.1556095. - DOI - PubMed
    1. Spasovski G, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol. Dial Transplant. 2014;170:G1–47. doi: 10.1007/s00134-014-3210-2. - DOI - PubMed
    1. Hannon MJ, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: Prevalence, causes and consequences. Eur. J. Endocrinol. 2010;162(Suppl 1):S5–12. doi: 10.1530/EJE-09-1063. - DOI - PubMed
    1. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am. J. Kidney Dis. 2008;52(1):144–153. doi: 10.1053/j.ajkd.2008.03.004. - DOI - PubMed
    1. Gómez-Valbuena I, Alonso-Pérez L, Alioto D, Cañamares-Orbis I, Ferrari-Piquero JM. Treatment with urea as an alternative to tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone. Farm. Hosp. 2014;38(4):379–380. doi: 10.7399/fh.2014.38.4.1112. - DOI - PubMed